CD24 is a promising immunotherapeutic target for enhancing efficacy of third-generation EGFR-TKIs on EGFR-mutated lung cancer

Abstract

Background: Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show initial efficacy in EGFR-mutated lung cancer, but residual disease persists. This study aimed to investigate cluster of differentiation 24 (CD24) as a translational immunotherapeutic target for enhancing third-generation EGFR-TKI efficacy.

Methods: We conducted RNA-sequencing (RNA-seq) on drug-responsive, drug-tolerant persister, and drug-resistant cells to identify therapeutic targets to pair with EGFR-TKIs. For validation, we integrated single-cell RNA-seq data from 29 lung cancer specimens and used single-nucleus RNA-seq and immunohistochemistry on clinical residual tumor samples following TKI therapy (TKI-residual). With CRISPR/Cas9, we studied the effect of CD24 on proliferation and phagocytic clearance during EGFR-TKI treatment. We tested CD24 knockout or ATG-031 (a first-in-class CD24 antibody) with EGFR-TKIs in vitro, xenografts, and spontaneous lung cancer models. To explore mechanisms, we used DNA affinity precipitation, chromatin immunoprecipitation sequencing, and luciferase assays to identify transcription factors regulating CD24. Co-immunoprecipitation combined with mass spectrometry and phosphoproteomics were used to study YIN-YANG-1 (YY1) S247 phosphorylation's expression and function, while kinase inhibitors assessed upstream phosphorylation of YY1 S247 and its regulation of CD24.

Results: CD24 expression rose in drug-responsive, -resistant, and -tolerant lung cancer cells and post-EGFR-TKI treatment clinical specimens. This elevation promoted cell proliferation and shielded tumor cells from macrophage-mediated phagocytosis. Genetic depletion of CD24 or treatment with ATG-031 significantly enhanced phagocytosis and tumor eradication in vitro, in xenografts, and in mice harboring EGFRL858R·T790M-driven spontaneous lung tumors. Furthermore, we revealed that YY1 S247 phosphorylation was responsible for the upregulation of CD24 upon EGFR-TKI treatment, facilitating YY1 dimerization and the formation of promoter-enhancer loops that regulate CD24 expression.

Conclusions: CD24 is a promising target in EGFR-mutated lung cancers, potentially enhancing efficacy of third-generation EGFR-TKIs.

Keywords

ATG-031 / CD24 / drug-tolerant persister cell / EGFR-TKI / lung cancer / osimertinib / phagocytosis / YY1 / JNK

References

[1] Hendriks LEL, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024;10(1):71.

[2] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.

[3] Diao X, Guo C, Jin Y, Li B, Gao X, Du X, et al. Cancer situation in China: an analysis based on the global epidemiological data released in 2024. Cancer Commun (Lond). 2025;45(2):178-97.

[4] Sondka Z, Dhir NB, Carvalho-Silva D, Jupe S, Madhumita , McLaren K, et al. COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res. 2024;52(D1):D1210-d7.

[5] Soo RA, Reungwetwattana T, Perroud HA, Batra U, Kilickap S, Tejado Gallegos LF, et al. Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study. J Thorac Oncol. 2024;19(10):1449-59.

[6] Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, et al. Management of locally advanced non-small cell lung cancer: State of the art and future directions. Cancer Commun (Lond). 2024;44(1):23-46.

[7] Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F, Ou SI. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. J Thorac Oncol. 2021;16(5):740-63.

[8] Zhang Y. Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor. Pharmacol Rev. 2023;75(6):1218-32.

[9] Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023;41(10):1830-40.

[10] Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, et al. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations. J Clin Oncol. 2022;40(27):3162-71.

[11] Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023;389(2):137-47.

[12] Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir Med. 2022;10(11):1019-28.

[13] Ahn MJ, Cho BC, Ou X, Walding A, Dymond AW, Ren S, et al. Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial. J Thorac Oncol. 2022;17(5):718-23.

[14] Yang JC, Shepherd FA, Kim DW, Lee GW, Lee JS, Chang GC, et al. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. J Thorac Oncol. 2019;14(5):933-9.

[15] Uphoff CC, Drexler HG. Detection of Mycoplasma contamination in cell cultures. Curr Protoc Mol Biol. 2014;106:28.4.1-28.4.14.

[16] Liang J, Bi G, Sui Q, Zhao G, Zhang H, Bian Y, et al. Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma. Cell Rep. 2024;43(2):113771.

[17] Hu C, Li T, Xu Y, Zhang X, Li F, Bai J, et al. CellMarker 2.0: an updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq data. Nucleic Acids Res. 2023;51(D1):D870-d6.

[18] Chen Z, Huang Y, Hu Z, Zhao M, Li M, Bi G, et al. Landscape and dynamics of single tumor and immune cells in early and advanced-stage lung adenocarcinoma. Clin Transl Med. 2021;11(3):e350.

[19] Zhao M, Chen Z, Zheng Y, Liang J, Hu Z, Bian Y, et al. Identification of cancer stem cell-related biomarkers in lung adenocarcinoma by stemness index and weighted correlation network analysis. J Cancer Res Clin Oncol. 2020;146(6):1463-72.

[20] Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286-99.

[21] UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 2023;51(D1):D523-d31.

[22] Sinitcyn P, Hamzeiy H, Salinas Soto F, Itzhak D, McCarthy F, Wichmann C, et al. MaxDIA enables library-based and library-free data-independent acquisition proteomics. Nat Biotechnol. 2021;39(12):1563-73.

[23] Chaparian RR, van Kessel JC. Promoter Pull-Down Assay: A Biochemical Screen for DNA-Binding Proteins. Methods Mol Biol. 2021;2346:165-72.

[24] Liang J, Bi G, Huang Y, Zhao G, Sui Q, Zhang H, et al. MAFF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating ferroptosis and cell cycle progression in lung adenocarcinoma. Drug Resist Updat. 2024;73:101057.

[25] Gavrilov A, Eivazova E, Priozhkova I, Lipinski M, Razin S, Vassetzky Y. Chromosome conformation capture (from 3C to 5C) and its ChIP-based modification. Methods Mol Biol. 2009;567:171-88.

[26] Russo M, Chen M, Mariella E, Peng H, Rehman SK, Sancho E, et al. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Nat Rev Cancer. 2024;24(10):694-717.

[27] Dou J, Pan M, Wen P, Li Y, Tang Q, Chu L, et al. Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Cell Mol Immunol. 2007;4(6):467-72.

[28] Liu C, Zhang Y, Gao J, Zhang Q, Sun L, Ma Q, et al. A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44(+)CD24(-) enriched breast cancer stem-like cells. Drug Resist Updat. 2023;66:100903.

[29] Roudi R, Madjd Z, Ebrahimi M, Samani FS, Samadikuchaksaraei A. CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549. Cell Mol Biol Lett. 2014;19(1):23-36.

[30] Wang TW, Chern E, Hsu CW, Tseng KC, Chao HM. SIRT1-Mediated Expression of CD24 and Epigenetic Suppression of Novel Tumor Suppressor miR-1185-1 Increases Colorectal Cancer Stemness. Cancer Res. 2020;80(23):5257-69.

[31] Hong P, Xu T, Xu J, Chen W, Hu H, Chen J, et al. CD24 promotes metastasis and chemoresistance by directly targeting Arf6-ERK pathway in esophageal squamous cell carcinoma. Cancer Lett. 2024;594:216994.

[32] Nakamura K, Terai Y, Tanabe A, Ono YJ, Hayashi M, Maeda K, et al. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways. Oncol Rep. 2017;37(6):3189-200.</bib

[33] Deng W, Gu L, Li X, Zheng J, Zhang Y, Duan B, et al. CD24 associates with EGFR and supports EGF/EGFR signaling via RhoA in gastric cancer cells. J Transl Med. 2016;14:32.

[34] Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392-6.

[35] Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 2009;323(5922):1722-5.

[36] Chen GY, Chen X, King S, Cavassani KA, Cheng J, Zheng X, et al. Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat Biotechnol. 2011;29(5):428-35.

[37] Liu Y, Chen GY, Zheng P. CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns. Trends Immunol. 2009;30(12):557-61.

[38] Sun Y, Wu L, Zhong Y, Zhou K, Hou Y, Wang Z, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184(2):404-21.e16.

[39] Luo Y, Hitz BC, Gabdank I, Hilton JA, Kagda MS, Lam B, et al. New developments on the Encyclopedia of DNA Elements (ENCODE) data portal. Nucleic Acids Res. 2020;48(D1):D882-d9.

[40] Li H, Sun L, Gao P, Hu H. Lactylation in cancer: Current understanding and challenges. Cancer Cell. 2024;42(11):1803-7.

[41] He M, Zhou X, Wang X. Glycosylation: mechanisms, biological functions and clinical implications. Signal Transduct Target Ther. 2024;9(1):194.

[42] Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534(7605):55-62.

[43] Zhang T, Keele GR, Gyuricza IG, Vincent M, Brunton C, Bell TA, et al. Multi-omics analysis identifies drivers of protein phosphorylation. Genome Biol. 2023;24(1):52.

[44] Hosea R, Hillary S, Wu S, Kasim V. Targeting Transcription Factor YY1 for Cancer Treatment: Current Strategies and Future Directions. Cancers (Basel). 2023;15(13):3506.

[45] Weintraub AS, Li CH, Zamudio AV, Sigova AA, Hannett NM, Day DS, et al. YY1 Is a Structural Regulator of Enhancer-Promoter Loops. Cell. 2017;171(7):1573-88.e28.

[46] Liu T, Zhu Q, Kai Y, Bingham T, Wang S, Cha HJ, et al. Matrin3 mediates differentiation through stabilizing chromatin loop-domain interactions and YY1 mediated enhancer-promoter interactions. Nat Commun. 2024;15(1):1274.

[47] Lam JC, Aboreden NG, Midla SC, Wang S, Huang A, Keller CA, et al. YY1-controlled regulatory connectivity and transcription are influenced by the cell cycle. Nat Genet. 2024;56(9):1938-52.

[48] Dao FY, Lv H, Zhang D, Zhang ZM, Liu L, Lin H. DeepYY1: a deep learning approach to identify YY1-mediated chromatin loops. Brief Bioinform. 2021;22(4):bbaa356.

[49] Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-9.

[50] Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630(8016):493-500.

[51] Johnson JL, Yaron TM, Huntsman EM, Kerelsky A, Song J, Regev A, et al. An atlas of substrate specificities for the human serine/threonine kinome. Nature. 2023;613(7945):759-66.

[52] Bi G, Liang J, Shan G, Bian Y, Chen Z, Huang Y, et al. Retinol Saturase Mediates Retinoid Metabolism to Impair a Ferroptosis Defense System in Cancer Cells. Cancer Res. 2023;83(14):2387-404.

[53] Zhang J, Xu C, Gao Y, Wang Y, Ding Z, Zhang Y, et al. A Novel Long Non-coding RNA, MSTRG.51053.2 Regulates Cisplatin Resistance by Sponging the miR-432-5p in Non-small Cell Lung Cancer Cells. Front Oncol. 2020;10:215.

[54] Bian Y, Shan G, Bi G, Liang J, Hu Z, Sui Q, et al. Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis. Redox Biol. 2024;77:103361.

[55] Haderk F, Chou YT, Cech L, Fernández-Méndez C, Yu J, Olivas V, et al. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat Commun. 2024;15(1):3741.

[56] Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, et al. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. J Thorac Oncol. 2015;10(6):910-23.

[57] Jiang XM, Xu YL, Huang MY, Zhang LL, Su MX, Chen X, et al. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. Acta Pharmacol Sin. 2017;38(11):1512-20.

[58] Lin K, Cheng J, Yang T, Li Y, Zhu B. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB. Biochem Biophys Res Commun. 2015;463(1-2):95-101.

[59] Shen W, Shi P, Dong Q, Zhou X, Chen C, Sui X, et al. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy. J Immunother Cancer. 2023;11(6):e007068.

[60] Zhang W, Zeng Y, Xiao Q, Wu Y, Liu J, Wang H, et al. An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses. Nat Commun. 2024;15(1):5670.

[61] Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell. 2024;42(11):1825-63.

[62] Brichkina A, Ems M, Suezov R, Singh R, Lutz V, Picard FSR, et al. DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer. Gut. 2024;73(10):1684-701.

[63] Liu Y, Ma J, Ma Y, Wang BZ, Wang Y, Yuan J, et al. Neutrophil extracellular traps impede cancer metastatic seeding via protease-activated receptor 2-mediated downregulation of phagocytic checkpoint CD24. J Immunother Cancer. 2025;13(2):e010813.

[64] Fu S, Piha-Paul SA, Singh S, Peng J, Keenan BP, Mei JM, et al. A first-in-human phase I study of ATG-031, anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM). Journal of Clinical Oncology. 2024;42(16_suppl): TPS2691-TPS.

[65] Shiiya A, Noguchi TA-O, Tomaru U, Ariga SA-O, Takashima Y, Ohhara Y, et al. EGFR inhibition in EGFR-mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment. Cancer Sci. 2023;114(4):1270-1283.

[66] Vaccaro K, Allen J, Whitfield TW, Maoz A, Reeves S, Velarde J, et al. Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction. J Clin Invest. 2024;134(9):e169315.

[67] Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, et al. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol. 2021;16(4):583-600.

[68] Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, et al. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell. 2023;41(2):340-55. e6.

[69] Shao F, Gao Y, Wang W, He H, Xiao L, Geng X, et al. Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade. Nat Cancer. 2022;3(10):1192-210.

[70] Suda K, Murakami I, Yu H, Kim J, Tan AC, Mizuuchi H, et al. CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to sEGFR Kinase Inhibitors in Lung Cancer. Mol Cancer Ther. 2018;17(10):2257-65.

[71] Fu M, Zhao J, Zhang L, Sheng Z, Li X, Qiu F, et al. Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade. Cancer Cell. 2024;42(11):1882-97.e7.

[72] Sun D, Hou H, Feng F, Wu W, Tan J, Xie T, et al. A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma. Exp Hematol Oncol. 2025;14(1):3.

[73] Agarwal N, Dancik GM, Goodspeed A, Costello JC, Owens C, Duex JE, et al. GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis. Cancer Res. 2016;76(17):5175-85.

[74] Rizkallah R, Hurt MM. Regulation of the transcription factor YY1 in mitosis through phosphorylation of its DNA-binding domain. Mol Biol Cell. 2009;20(22):4766-76.

[75] Verheul TCJ, van Hijfte L, Perenthaler E, Barakat TS. The Why of YY1: Mechanisms of Transcriptional Regulation by Yin Yang 1. Front Cell Dev Biol. 2020;8:592164.

[76] Wei SY, Shih YT, Wu HY, Wang WL, Lee PL, Lee CI, et al. Endothelial Yin Yang 1 Phosphorylation at S118 Induces Atherosclerosis Under Flow. Circ Res. 2021;129(12):1158-74.

[77] Li Y, Li C, Sun Q, Liu X, Chen F, Cheung Y, et al. Skeletal muscle stem cells modulate niche function in Duchenne muscular dystrophy mouse through YY1-CCL5 axis. Nat Commun. 2025;16(1):1324.

[78] Huang J, Wang X, Li N, Fan W, Li X, Zhou Q, et al. YY1 Lactylation Aggravates Autoimmune Uveitis by Enhancing Microglial Functions via Inflammatory Genes. Adv Sci (Weinh). 2024;11(19):e2308031.

[79] Li Y, Li J, Li Z, Wei M, Zhao H, Miyagishi M, et al. Homeostasis Imbalance of YY2 and YY1 Promotes Tumor Growth by Manipulating Ferroptosis. Adv Sci (Weinh). 2022;9(13):e2104836.

[80] Guo G, Gong K, Ali S, Ali N, Shallwani S, Hatanpaa KJ, et al. A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. Nat Neurosci. 2017;20(8):1074-84.

[81] Lu PH, Kuo TC, Chang KC, Chang CH, Chu CY. Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway. Br J Dermatol. 2011;164(1):38-46.

[82] Manole S, Richards EJ, Meyer AS. JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2-Targeted Therapies. Cancer Res. 2016;76(18):5219-28.

[83] Wu Q, Wu W, Fu B, Shi L, Wang X, Kuca K. JNK signaling in cancer cell survival. Med Res Rev. 2019;39(6):2082-104.

[84] Devaiah BN, Singh AK, Mu J, Chen Q, Meerzaman D, Singer DS. Phosphorylation by JNK switches BRD4 functions. Mol Cell. 2024;84(22):4282-96. e7.

[85] Lin X, Ye R, Li Z, Zhang B, Huang Y, Du J, et al. KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/MAPK pathway in an m(6)A-dependent manner. Drug Resist Updat. 2023;66:100908.

[86] Luo MY, Zhou Y, Gu WM, Wang C, Shen NX, Dong JK, et al. Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma. Cancer Res. 2022;82(19):3516-31.

[87] Maity TK, Kim EY, Cultraro CM, Venugopalan A, Khare L, Poddutoori R, et al. Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance. Cancers (Basel). 2023;15(8):2263.

[88] Neveu G, Ziv-Av A, Barouch-Bentov R, Berkerman E, Mulholland J, Einav S. AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets. J Virol. 2015;89(8):4387-404.

[89] Terai H, Kitajima S, Potter DS, Matsui Y, Quiceno LG, Chen T, et al. ER Stress Signaling Promotes the Survival of Cancer “Persister Cells” Tolerant to EGFR Tyrosine Kinase Inhibitors. Cancer Res. 2018;78(4):1044-57.

[90] Xia L, Zheng Z, Liu JY, Chen YJ, Ding J, Hu GS, et al. Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition. Cancer Immunol Res. 2021;9(6):707-22.

[91] Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15(1):173.

[92] Boch T, Köhler J, Janning M, Loges S. Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives. Cancer Biol Med. 2022;19(11):1543-64.

[93] Wei Y, Liu M, Yen EY, Yao J, Nguyen PT, Wang X, et al. KRAS inhibition activates an actionable CD24 ‘don't eat me’ signal in pancreas cancer. bioRxiv. 2023.

[94] Li X, Tian W, Jiang Z, Song Y, Leng X, Yu J. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions. Cancer Immunol Immunother. 2024;73(2):31.

[95] Hazra R, Chattopadhyay S, Mallick A, Gayen S, Roy S. Unravelling CD24-Siglec-10 pathway: Cancer immunotherapy from basic science to clinical studies. Immunology. 2024;173(3):442-69.

[96] Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164(12):6166-73.

[97] Locati M, Curtale G, Mantovani A. Diversity, Mechanisms, and Significance of Macrophage Plasticity. Annu Rev Pathol. 2020;15:123-47.

RIGHTS & PERMISSIONS

2025 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd on behalf of Sun Yat-sen University Cancer Center.